{"success":true,"data":{"pressRelease":{"id":"134533","rtpr_id":"nGNX9fLcf8","ticker":"CAPR","exchange":"NASDAQ","all_tickers":["CAPR"],"title":"Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel Amid Ongoing Securities Class Action and September 28 Lead Plaintiff Deadline","author":"Globe Newswire","published_at":"2026-09-02T22:59:26.107Z","article_body":"SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro\nLLP—a national plaintiffs’ rights law firm with a premier securities\npractice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ:\nCAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the\nongoing securities class action. This alert follows the U.S. Food and Drug\nAdministration's (FDA) recent decision to extend the review period for\nCapricor's Biologics License Application (BLA), underscoring the ongoing\nregulatory and disclosure scrutiny surrounding the company.\n\nHagens Berman encourages investors in Capricor Therapeutics, Inc. (NASDAQ:\nCAPR) who suffered substantial losses to submit your losses now\n(https://www.globenewswire.com/Tracker?data=uiTuTfLLLFtB-R0nSfGuMzq-CFkDiLWUSJOZJWQPeIUGiMAztyN00SGQ3GGti7WaTyyltjYYf55dfy80qE2QFY4AnyJUUy4n42hsyXNOGtH8SCOZJ33-r2rWrRpphhzUqqrP8s_11frU7EwuRXZa4Oig35jeHMomG2mw7r9FgcqIybBFIUp0kwPuJm0OBbT1).\n\nFDA Extends BLA Review Following Post-AdCom Submissions\n\nOn Aug. 24, Capricor announced that the FDA has extended the Prescription Drug\nUser Fee Act (PDUFA) target action date for Capricor’s lead investigational\ncell therapy, deramiocel, for the treatment of Duchenne muscular dystrophy\n(DMD), moving the decision date from August 22, 2026, to November 22, 2026.\n\nThe agency classified Capricor’s recent submission—which follows a\nturbulent July 2026 Advisory Committee meeting and includes 24-month\nopen-label extension data from the Phase 3 HOPE-3 study alongside a request to\npivot toward a refined indication focused solely on upper limb function—as a\nmajor amendment.\n\nSecurities Class Action Details & Overview\n* Class Period: Dec. 17, 2025 – July 26, 2026\n* Lead Plaintiff Deadline: Sept. 28, 2026\n* Visit: www.hbsslaw.com/capr\n* Contact the Firm Now: CAPR@hbsslaw.com / 844-916-0895\nCore Allegations and Background\n* Material Misleading Statements Regarding Clinical Trial Data and SAP\nChanges: The lawsuit alleges that Capricor and certain executives made\nmaterially false and misleading statements regarding the clinical trial data\nand regulatory pathway for its lead product candidate, Deramiocel, intended to\ntreat Duchenne muscular dystrophy (DMD). Specifically, defendants allegedly\nfailed to disclose that they adopted changes to the pre-specified statistical\nanalysis plan (SAP) without agreement from the U.S. Food and Drug\nAdministration (FDA) prior to resubmitting its Biologics License Application\n(BLA).\n\n* The HOPE-3 Trial Breakthrough and Subsequent Capital Raise: On December 3,\n2025 Capricor announced “Positive Topline Results from Pivotal Phase 3\nHOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy.” The company’s\nCEO said, “HOPE-3 delivered strong and definitive evidence that Deramiocel\ncan meaningfully improve the course of Duchenne muscular dystrophy,\ndemonstrating statistically significant improvements in both skeletal and\ncardiac function.” Driven by these claims, Capricor's share price surged\n370% to close up $23.60 on December 3, 2025. The following day, the company\nlaunched a public stock offering of approximately 6 million shares priced at\n$25 per share.\n\n* FDA Briefing Document Reveals SAP Changes and Triggers 64% Stock Collapse:\nCapricor’s public assurances unraveled on July 27, 2026, when the FDA\npublished briefing documents ahead of an Advisory Committee meeting. The\ndocuments revealed that Capricor made unagreed-upon post-hoc modifications to\nits pre-specified Statistical Analysis Plan (SAP). The FDA stated that the\nHOPE-3 study “did not meet its pre-specified primary and secondary efficacy\nendpoints showing no statistically significant difference between deramiocel\nand placebo at 12 months.” Capricor shares crashed roughly 64% in a single\nday to close at $7.00. An Advisory Committee subsequently voted 9–3 against\nthe efficacy of the drug, compounding investor losses.\nHagens Berman’s Investigation\n\n“We're focused on investors’ losses and uncovering the full scope of how\nmanagement characterized these trial endpoints and undisclosed\nmodification,” said Reed Kathrein\n(https://www.globenewswire.com/Tracker?data=GiBaWlxezhS8lsy46rzNIUvv6j0uhCU2XnLKc2WdjQqvyw8FEzFzn_LpA9pAXBltUx4yq4Gbxv6D6SaIjOpTZKBee4u1YkFBxD7RtCx3DD3V0XsaOaOU8h3SwNkY48cA),\nthe Hagens Berman partner leading the firm’s investigation on the claims\nalleged in the pending suit.\n\nWhat Affected CAPR Investors Should Do\nIf you purchased or acquired Capricor securities between December 17, 2025,\nand July 26, 2026, and suffered significant financial losses, you have until\nSeptember 28, 2026, to ask the court to appoint you as lead plaintiff. You do\nnot need to seek lead plaintiff status to share in any potential recovery.\n\nTo learn more about your legal options, submit your information to Hagens\nBerman\n(https://www.globenewswire.com/Tracker?data=uiTuTfLLLFtB-R0nSfGuM90HSJL1i-ldjoJFGt7CHDXKLIJZvwRGx8lUr3m4CTVqFGh6uHDHMxbtTkfsRbMnEX4rwVEsaZnS0VRKbIEQQ38VbWKJ0LB9hTmO8SeHbL0MpzoL7yP2ZE5FeXIDmGgr4OCxXkmo0h43bqjS0b0EcsiwWBYCDPBJcDyZ7pwpK1oEIj60oc70NrvHMt5KTnNTwg==),\nvisit www.hbsslaw.com/capr, call Reed Kathrein at 844-916-0895, or email\nCAPR@hbsslaw.com.\n\nIf you’d like more information and answers to frequently asked questions\nabout the Capricor case and the firm’s investigation, read more\n(https://www.globenewswire.com/Tracker?data=NmvoSpkSq6tV4U_VU2-bS-tWShM8bpyxvWEJ9QxOj6anBaXIv2N8w0Sgq1nm-Q7-pBS4N_H5p6TJ2wTyViXeKxS458hqtKLSrJFv3NU9yAKplGoRmy8GPqfcd-KE7wjR6jYGNujt7m9oW5N9PQdtm3543Koankqjv9gX6WjMxsg=)\n»\n(https://www.globenewswire.com/Tracker?data=5vnF4E2v87oRddSkeyL7tkvppsh9M5ZV-p24my2hvobsEFNGu05CTq_nL3UaSxF9yY5LZ8rPttby2q7nCmsP4Ku9FivX89Jr3tVbMzyhndXJtl7tNMGqGZxYini73BTiifScfoTyrxDbI2i-W-3NlZolZZLcdX6w5Za4EsUe0LM=)\n\nWhistleblowers: Persons with non-public information regarding Capricor should\nconsider their options to help in the investigation or take advantage of the\nSEC Whistleblower program. Under the new program, whistleblowers who provide\noriginal information may receive rewards totaling up to 30 percent of any\nsuccessful recovery made by the SEC. For more information, call Reed Kathrein\nat 844-916-0895 or email CAPR@hbsslaw.com.\n\nAbout Hagens Berman\n(https://www.globenewswire.com/Tracker?data=Up9VlXHzQNkRV9Mhe1HlunOjYC34bz-rm54YGbk7IMe5PmsOjMs2L3hwKlUgwc1393AoNZBxH4n_DSTLUpT7soegCz-tmnl5IgpZFaKpk2Q=)\nHagens Berman is a global plaintiffs’ rights complex litigation firm\nfocusing on corporate accountability. The firm is home to a robust practice\nand represents investors as well as whistleblowers, workers, consumers and\nothers in cases achieving real results for those harmed by corporate\nnegligence and other wrongdoings. Hagens Berman’s team has secured more than\n$2.9 billion in this area of law. More about the firm and its successes can be\nfound at hbsslaw.com\n(https://www.globenewswire.com/Tracker?data=OawU2IUrhVn4ZZjXdMFBhJ4kHz2oycWojflcqZoRIAZuboLcYcqKWp_8NlExEarDIwb0ctybJELAztARSx3T3Q==).\nFollow the firm for updates and news at @ClassActionLaw. \n\nAttorney Advertising. Prior results do not guarantee a similar outcome in any\nfuture case.\n\nContact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300,\nBerkeley, CA 94710, 844-916-0895, CAPR@hbsslaw.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2c81cd72-0ffb-43c9-9d0f-b622c3e44e43)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9fLcf8","title":"Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel Amid Ongoing Securities Class Action and September 28 Lead Plaintiff Deadline","author":"Globe Newswire","ticker":"CAPR","created":"2026-09-02T22:59:26.107Z","tickers":["CAPR"],"exchange":"NASDAQ","article_body":"SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro\nLLP—a national plaintiffs’ rights law firm with a premier securities\npractice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ:\nCAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the\nongoing securities class action. This alert follows the U.S. Food and Drug\nAdministration's (FDA) recent decision to extend the review period for\nCapricor's Biologics License Application (BLA), underscoring the ongoing\nregulatory and disclosure scrutiny surrounding the company.\n\nHagens Berman encourages investors in Capricor Therapeutics, Inc. (NASDAQ:\nCAPR) who suffered substantial losses to submit your losses now\n(https://www.globenewswire.com/Tracker?data=uiTuTfLLLFtB-R0nSfGuMzq-CFkDiLWUSJOZJWQPeIUGiMAztyN00SGQ3GGti7WaTyyltjYYf55dfy80qE2QFY4AnyJUUy4n42hsyXNOGtH8SCOZJ33-r2rWrRpphhzUqqrP8s_11frU7EwuRXZa4Oig35jeHMomG2mw7r9FgcqIybBFIUp0kwPuJm0OBbT1).\n\nFDA Extends BLA Review Following Post-AdCom Submissions\n\nOn Aug. 24, Capricor announced that the FDA has extended the Prescription Drug\nUser Fee Act (PDUFA) target action date for Capricor’s lead investigational\ncell therapy, deramiocel, for the treatment of Duchenne muscular dystrophy\n(DMD), moving the decision date from August 22, 2026, to November 22, 2026.\n\nThe agency classified Capricor’s recent submission—which follows a\nturbulent July 2026 Advisory Committee meeting and includes 24-month\nopen-label extension data from the Phase 3 HOPE-3 study alongside a request to\npivot toward a refined indication focused solely on upper limb function—as a\nmajor amendment.\n\nSecurities Class Action Details & Overview\n* Class Period: Dec. 17, 2025 – July 26, 2026\n* Lead Plaintiff Deadline: Sept. 28, 2026\n* Visit: www.hbsslaw.com/capr\n* Contact the Firm Now: CAPR@hbsslaw.com / 844-916-0895\nCore Allegations and Background\n* Material Misleading Statements Regarding Clinical Trial Data and SAP\nChanges: The lawsuit alleges that Capricor and certain executives made\nmaterially false and misleading statements regarding the clinical trial data\nand regulatory pathway for its lead product candidate, Deramiocel, intended to\ntreat Duchenne muscular dystrophy (DMD). Specifically, defendants allegedly\nfailed to disclose that they adopted changes to the pre-specified statistical\nanalysis plan (SAP) without agreement from the U.S. Food and Drug\nAdministration (FDA) prior to resubmitting its Biologics License Application\n(BLA).\n\n* The HOPE-3 Trial Breakthrough and Subsequent Capital Raise: On December 3,\n2025 Capricor announced “Positive Topline Results from Pivotal Phase 3\nHOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy.” The company’s\nCEO said, “HOPE-3 delivered strong and definitive evidence that Deramiocel\ncan meaningfully improve the course of Duchenne muscular dystrophy,\ndemonstrating statistically significant improvements in both skeletal and\ncardiac function.” Driven by these claims, Capricor's share price surged\n370% to close up $23.60 on December 3, 2025. The following day, the company\nlaunched a public stock offering of approximately 6 million shares priced at\n$25 per share.\n\n* FDA Briefing Document Reveals SAP Changes and Triggers 64% Stock Collapse:\nCapricor’s public assurances unraveled on July 27, 2026, when the FDA\npublished briefing documents ahead of an Advisory Committee meeting. The\ndocuments revealed that Capricor made unagreed-upon post-hoc modifications to\nits pre-specified Statistical Analysis Plan (SAP). The FDA stated that the\nHOPE-3 study “did not meet its pre-specified primary and secondary efficacy\nendpoints showing no statistically significant difference between deramiocel\nand placebo at 12 months.” Capricor shares crashed roughly 64% in a single\nday to close at $7.00. An Advisory Committee subsequently voted 9–3 against\nthe efficacy of the drug, compounding investor losses.\nHagens Berman’s Investigation\n\n“We're focused on investors’ losses and uncovering the full scope of how\nmanagement characterized these trial endpoints and undisclosed\nmodification,” said Reed Kathrein\n(https://www.globenewswire.com/Tracker?data=GiBaWlxezhS8lsy46rzNIUvv6j0uhCU2XnLKc2WdjQqvyw8FEzFzn_LpA9pAXBltUx4yq4Gbxv6D6SaIjOpTZKBee4u1YkFBxD7RtCx3DD3V0XsaOaOU8h3SwNkY48cA),\nthe Hagens Berman partner leading the firm’s investigation on the claims\nalleged in the pending suit.\n\nWhat Affected CAPR Investors Should Do\nIf you purchased or acquired Capricor securities between December 17, 2025,\nand July 26, 2026, and suffered significant financial losses, you have until\nSeptember 28, 2026, to ask the court to appoint you as lead plaintiff. You do\nnot need to seek lead plaintiff status to share in any potential recovery.\n\nTo learn more about your legal options, submit your information to Hagens\nBerman\n(https://www.globenewswire.com/Tracker?data=uiTuTfLLLFtB-R0nSfGuM90HSJL1i-ldjoJFGt7CHDXKLIJZvwRGx8lUr3m4CTVqFGh6uHDHMxbtTkfsRbMnEX4rwVEsaZnS0VRKbIEQQ38VbWKJ0LB9hTmO8SeHbL0MpzoL7yP2ZE5FeXIDmGgr4OCxXkmo0h43bqjS0b0EcsiwWBYCDPBJcDyZ7pwpK1oEIj60oc70NrvHMt5KTnNTwg==),\nvisit www.hbsslaw.com/capr, call Reed Kathrein at 844-916-0895, or email\nCAPR@hbsslaw.com.\n\nIf you’d like more information and answers to frequently asked questions\nabout the Capricor case and the firm’s investigation, read more\n(https://www.globenewswire.com/Tracker?data=NmvoSpkSq6tV4U_VU2-bS-tWShM8bpyxvWEJ9QxOj6anBaXIv2N8w0Sgq1nm-Q7-pBS4N_H5p6TJ2wTyViXeKxS458hqtKLSrJFv3NU9yAKplGoRmy8GPqfcd-KE7wjR6jYGNujt7m9oW5N9PQdtm3543Koankqjv9gX6WjMxsg=)\n»\n(https://www.globenewswire.com/Tracker?data=5vnF4E2v87oRddSkeyL7tkvppsh9M5ZV-p24my2hvobsEFNGu05CTq_nL3UaSxF9yY5LZ8rPttby2q7nCmsP4Ku9FivX89Jr3tVbMzyhndXJtl7tNMGqGZxYini73BTiifScfoTyrxDbI2i-W-3NlZolZZLcdX6w5Za4EsUe0LM=)\n\nWhistleblowers: Persons with non-public information regarding Capricor should\nconsider their options to help in the investigation or take advantage of the\nSEC Whistleblower program. Under the new program, whistleblowers who provide\noriginal information may receive rewards totaling up to 30 percent of any\nsuccessful recovery made by the SEC. For more information, call Reed Kathrein\nat 844-916-0895 or email CAPR@hbsslaw.com.\n\nAbout Hagens Berman\n(https://www.globenewswire.com/Tracker?data=Up9VlXHzQNkRV9Mhe1HlunOjYC34bz-rm54YGbk7IMe5PmsOjMs2L3hwKlUgwc1393AoNZBxH4n_DSTLUpT7soegCz-tmnl5IgpZFaKpk2Q=)\nHagens Berman is a global plaintiffs’ rights complex litigation firm\nfocusing on corporate accountability. The firm is home to a robust practice\nand represents investors as well as whistleblowers, workers, consumers and\nothers in cases achieving real results for those harmed by corporate\nnegligence and other wrongdoings. Hagens Berman’s team has secured more than\n$2.9 billion in this area of law. More about the firm and its successes can be\nfound at hbsslaw.com\n(https://www.globenewswire.com/Tracker?data=OawU2IUrhVn4ZZjXdMFBhJ4kHz2oycWojflcqZoRIAZuboLcYcqKWp_8NlExEarDIwb0ctybJELAztARSx3T3Q==).\nFollow the firm for updates and news at @ClassActionLaw. \n\nAttorney Advertising. Prior results do not guarantee a similar outcome in any\nfuture case.\n\nContact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300,\nBerkeley, CA 94710, 844-916-0895, CAPR@hbsslaw.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2c81cd72-0ffb-43c9-9d0f-b622c3e44e43)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-02T22:59:26.149766235Z","server_sent_at_ms":1788389966149},"received_at":"2026-09-02T22:59:26.210Z","source_url":null},"analysis":{"id":"123423","press_release_id":"134533","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["ongoing securities class action alleging undisclosed post-hoc changes to the pre-specified statistical analysis plan before the BLA resubmission","FDA extended deramiocel PDUFA date from Aug. 22 to Nov. 22, 2026 after classifying the submission as a major amendment","FDA briefing documents stated HOPE-3 missed its pre-specified primary and secondary endpoints","AdCom voted 9-3 against deramiocel efficacy; shares fell roughly 64% to $7.00 on July 27, 2026","December 2025 capital raise (~6M shares at $25) came immediately after the positive HOPE-3 topline announcement now central to the litigation"],"eventType":"legal_litigation","narrative":"Hagens Berman issued a plaintiff-solicitation alert naming Capricor Therapeutics, reminding investors of the September 28, 2026 lead plaintiff deadline in the pending securities class action; the class period runs December 17, 2025 through July 26, 2026.\n\nThe release recaps that the FDA extended the PDUFA target action date for deramiocel, Capricor's lead cell therapy for Duchenne muscular dystrophy, from August 22, 2026 to November 22, 2026 after classifying the company's post-AdCom submission as a major amendment.\n\nBackground cited includes a roughly 64% one-day share collapse to $7.00 on July 27, 2026 after FDA briefing documents said the HOPE-3 study missed its pre-specified endpoints, followed by a 9-3 advisory committee vote against efficacy, as well as a December 2025 surge of 370% and an offering of approximately 6 million shares at $25.\n\nNo new issuer disclosure or court action is announced in this release; it is contingency-fee law-firm marketing and should be treated as low-signal noise.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Suppress -- plaintiff-firm solicitation recapping known CAPR FDA delay and class action; no new disclosure."},"keyFigures":{"offeringPrice":25,"sharesOffered":"approximately 6 million","customDimensions":{"adcom_vote":"9-3 against efficacy","class_period":"Dec. 17, 2025 - July 26, 2026","dec_2025_close_gain":"$23.60","pdufa_extended_date":"November 22, 2026","pdufa_original_date":"August 22, 2026","lead_plaintiff_deadline":"Sept. 28, 2026","stock_close_after_crash":"$7.00","amendment_classification":"major amendment","stock_surge_pct_dec_2025":"370%","stock_crash_pct_july_2026":"roughly 64%","historical_offering_context":"December 2025 public offering of approximately 6 million shares at $25 per share"}},"quotedText":"did not meet its pre-specified primary and secondary efficacy\nendpoints showing no statistically significant difference between deramiocel\nand placebo at 12 months.","namedEntities":{"people":[{"name":"Reed Kathrein","role":"Hagens Berman partner leading the investigation"}],"products":["deramiocel"],"companies":[{"name":"Capricor Therapeutics, Inc.","ticker":"CAPR","relationship":"issuer and class-action defendant"},{"name":"Hagens Berman Sobol Shapiro LLP","relationship":"plaintiff law firm / release author"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"$25","context":"per-share price of the December 2025 public stock offering"},{"amount":"$23.60","context":"share-price gain when CAPR closed up 370% on Dec. 3, 2025"},{"amount":"$7.00","context":"share price after the roughly 64% one-day collapse on July 27, 2026"},{"amount":"$2.9 billion","context":"Hagens Berman's cumulative recoveries in its areas of practice"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued under Hagens Berman's own name seeking lead plaintiffs before the Sept. 28, 2026 deadline. It only recaps previously disclosed events (FDA PDUFA extension, AdCom vote, pending class action); no certified class, no settlement, and no new issuer disclosure."},"tickerRelevance":{"others":[],"primary":"CAPR"},"globalImportance":22,"audienceRelevance":18,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small/mid-cap biotech","eventGravity":"law-firm-solicitation","issuerAuthored":false,"newInformation":"none - all facts previously disclosed","retailFavoriteBoost":"moderate - binary FDA-event biotech with retail following","underlyingEventRecap":"FDA PDUFA extension and pending securities class action"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Hagens Berman issued a plaintiff-solicitation alert naming Capricor Therapeutics, reminding investors of the September 28, 2026 lead plaintiff deadline in the pending securities class action; the class period runs December 17, 2025 through July 26, 2026.\n\nThe release recaps that the FDA extended the PDUFA target action date for deramiocel, Capricor's lead cell therapy for Duchenne muscular dystrophy, from August 22, 2026 to November 22, 2026 after classifying the company's post-AdCom submission as a major amendment.\n\nBackground cited includes a roughly 64% one-day share collapse to $7.00 on July 27, 2026 after FDA briefing documents said the HOPE-3 study missed its pre-specified endpoints, followed by a 9-3 advisory committee vote against efficacy, as well as a December 2025 surge of 370% and an offering of approximately 6 million shares at $25.\n\nNo new issuer disclosure or court action is announced in this release; it is contingency-fee law-firm marketing and should be treated as low-signal noise.","key_figures":{"offeringPrice":25,"sharesOffered":"approximately 6 million","customDimensions":{"adcom_vote":"9-3 against efficacy","class_period":"Dec. 17, 2025 - July 26, 2026","dec_2025_close_gain":"$23.60","pdufa_extended_date":"November 22, 2026","pdufa_original_date":"August 22, 2026","lead_plaintiff_deadline":"Sept. 28, 2026","stock_close_after_crash":"$7.00","amendment_classification":"major amendment","stock_surge_pct_dec_2025":"370%","stock_crash_pct_july_2026":"roughly 64%","historical_offering_context":"December 2025 public offering of approximately 6 million shares at $25 per share"}},"named_entities":{"people":[{"name":"Reed Kathrein","role":"Hagens Berman partner leading the investigation"}],"products":["deramiocel"],"companies":[{"name":"Capricor Therapeutics, Inc.","ticker":"CAPR","relationship":"issuer and class-action defendant"},{"name":"Hagens Berman Sobol Shapiro LLP","relationship":"plaintiff law firm / release author"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"$25","context":"per-share price of the December 2025 public stock offering"},{"amount":"$23.60","context":"share-price gain when CAPR closed up 370% on Dec. 3, 2025"},{"amount":"$7.00","context":"share price after the roughly 64% one-day collapse on July 27, 2026"},{"amount":"$2.9 billion","context":"Hagens Berman's cumulative recoveries in its areas of practice"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-02T23:01:05.416Z","global_importance":22,"audience_relevance":18,"importance_components":{"tickerTier":"small/mid-cap biotech","eventGravity":"law-firm-solicitation","issuerAuthored":false,"newInformation":"none - all facts previously disclosed","retailFavoriteBoost":"moderate - binary FDA-event biotech with retail following","underlyingEventRecap":"FDA PDUFA extension and pending securities class action"}},"durationMs":99196,"modelName":"glm-4.7"}}